Amylyx Pharmaceuticals, Inc.
AMLX
$3.63
-$0.045-1.23%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 48.36% | -0.01% | 38.80% | -2,610.95% | -77.36% |
| Total Depreciation and Amortization | -27.60% | 6.25% | -33.97% | 4.65% | -0.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -87.76% | 184.18% | -87.60% | 1,592.40% | -9.51% |
| Change in Net Operating Assets | -151.99% | -21.87% | -5,401.83% | -89.47% | 104.57% |
| Cash from Operations | -41.95% | 37.56% | -13,515.54% | -103.61% | 362.16% |
| Capital Expenditure | 99.94% | -40,556.18% | -32.84% | 81.18% | 0.28% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -13.33% | 359.77% | -3,358.69% | -95.84% | 119.75% |
| Cash from Investing | 67.41% | 234.03% | -3,636.14% | -96.09% | 119.36% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -69.86% | 944.68% | -96.75% | 316.71% | -64.74% |
| Repurchase of Common Stock | 90.75% | -1,955.00% | 98.48% | -1,023.93% | -23.16% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 37.50% | 196.30% | -79.39% | -43.04% | -74.13% |
| Foreign Exchange rate Adjustments | -322.46% | 705.13% | 64.55% | -146.41% | 276.87% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 327.93% | 97.45% | -27,323.08% | -99.00% | 131.06% |
